Rodman & Renshaw analyst Seema Sheoran initiates coverage on Neurogene (NASDAQ: NGNE) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot New Coverage New Coverage